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Background: Cervical cancer incidence is low in Saudi Arabian women, suggesting low prevalence to HPV
infection due to environmental, cultural and genetic differences. Therefore, we investigated HPV prevalence and
genotype distribution in cervical cancer as well as the association with 9 genetic single nucleotide polymorphisms
(SNPs): CDKN1A (p21) C31A, TP53 C72G, ATM G1853A, HDM2 promoter T309G, HDM2 A110G, LIG4 A591G, XRCC1
G399A, XRCC3 C241T and TGFβ1 T10C, presumed to predispose to cancer.
Methods: One hundred cervical cancer patients (90 squamous cell carcinoma and 10 adenocarcinoma) and 100
age/sex-matched controls were enrolled. SNPs were genotyped by direct sequencing and HPV was detected and
typed in tumors using the HPV Linear Array Test.
Results: Eighty-two cases (82%) were positive for HPV sequences. Seven HPV genotypes were present as single
infections (16, 18, 31, 45, 56, 59, 73) and five double infections (16/18, 16/39, 16/70, 35/52, 45/59) were detected.
Most common genotypes were HPV-16 (71%), 31 (7%), and 18, 45, 73 (4% each). Only XRCC1 SNP was significantly
associated with cervical cancer (P=0.02, OD=1.69; 95% CI= 1.06–2.66). However, nested analysis revealed a
preponderance of HPV-positivity in patients harboring the presumed risk allele TP53 G (P=0.06). Both XRCC1 and
TP53 SNPs tended to deviate from Hardy-Weinberg equilibrium (HWE; P=0.03-0.07).
Conclusions: HPV prevalence (82%) in cervical cancer is at the lower range of the worldwide estimation (85 - 99%).
While XRCC1 G399A was significantly associated with cervical cancer, TP53 G72C showed borderline association only
in HPV-positive patients. Deviation from HWE in HPV-positive patients indicates co-selection, hence implicating the
combination of HPV and SNPs in cancer predisposition. Thus, SNPs could be more relevant biomarkers of
susceptibility to cervical cancer when associated with HPV infection.
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Cancer of the uterine cervix is the 3rd most frequent
malignancy affecting women worldwide and the seventh
overall, with an estimated 530,000 new cases in 2008
[1,2]. Among all the known risk factors, human papillo-
mavirus (HPV) stands as a main cause, and high-risk
HPV infections play a major role in the pathogenesis of
cervical cancer with an estimated prevalence between
85% to 99% [3-7]. More than 85% of the global burden
occurs in developing countries, where it accounts for* Correspondence: galsbeih@kfshrc.edu.sa
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reproduction in any medium, provided the or13% of all female cancers. This is due to the lack of
proper screening program that has helped reducing
cervical cancer incidence and mortality rates by 70% in
developed countries [8,9].
In contrast to the global view, the incidence of cervical
cancer is very low in Saudi Arabia, ranking number 11
between all cancers in females and accounts only for
2.4% of all new cases [10], despite the lack of national
screening programs. The actual reason for this low inci-
dence is unknown. The closed society and standards of
mores could reduce women exposure to HPV infection
[11-14]. In addition, male circumcision is associated with
a reduced risk of penile HPV infection and a reduced
risk of cervical cancer in their female partners [15]. The
prevalence of HPV infection among women and itsis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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similar socio-cultural societies is scanty [14,16-20]. In a
limited study performed on 120 women attending routine
gynecological examination, Al-Muammar et al. reported a
prevalence of 31.6% infection with HPV-16/18 [21]. In
addition, early reports are discordant [22,23], particularly
that some show high incidence, such as in Indonesia,
where cervical cancer ranks number 3 after breast and
colorectal tumors [2].
Inherited genetic predisposition may contribute to the
risk of cervical cancer. Genetic polymorphisms in tumor
suppressor genes might be related to HPV persistence
and progression to cancer. The gene encoding the tumor
suppressor TP53 is one example of a candidate gene that
has been suggested to affect the oncogenic potential of
the HPV E6 protein. A common polymorphism in the
p53 amino acid sequence is the arginine or proline at
position 72 (G/C) (rs1042522). Storey et al. found an
association between the majority allele, arginine (G) form
of p53, and cervical cancer development and proposed
that this genotype is more susceptible to HPV E6-
mediated degradation [24]. Since then, there have been
many reports on this TP53 polymorphism and risk for
cervical cancer and the results are largely contradictory






































Maintain Genomic Stability: Cell R
FA Complex:
A C D E F G
Figure 1 Schematic representation of main pathways involved in pro
DNA single-strand breaks (SSBs) and double-strand breaks (DSBs). BD
mechanisms. DSBs are repaired by non-homologous end joining (NHEJ) an
interacting proteins in tissues, cells and mitochondria that lead to the expr
cycle arrest to allow for accurate DNA healing to prevent the cells from en
genomic integrity which enables recovery or otherwise triggers cell death.
respectively interact with TP53 and RB tumor suppressor proteins and inhib
interactions. Arrows indicate activation and blunt ends indicate inhibition. T
designates encoding genes selected for polymorphic variations predisposinand its relationship with HPV infection and cervical
cancer is still unknown among Saudi women. In addition,
TP53 is a central node in cell cycle control and DNA
repair and orchestrates multiple pathways to maintain
genomic integrity that can be compromised by HPV infec-
tion (Figure 1). The following SNPs: CDKN1A C31A Ser/
Arg (rs1801270), ATM G1853A Asp/Asn (rs1801516),
HDM2 T309G promoter (rs2279744), HDM2 A110G Ile/
Val (rs11177386), LIG4 A591G Ile/Val (rs2232641),
XRCC1 G399A Arg/Gln (rs25487), XRCC3 C241T Thr/
Met (rs861539) and TGFβ1 T10C Lue/Pro (rs1982073)
selected from various pathways could also alter protein
function and contribute to p53-mediated cell cycle dere-
gulation and genomic instability [27-29]. Therefore, the
aims of this study were to investigate HPV prevalence and
genotype in our cervical cancer patients and the potential




One hundred patients with histopathologically proven,
locally advanced, cervical cancer were enrolled in this
study out of 218 patients followed at King Faisal Specialist
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logical type of cervix cancer (squamous cell carcinoma,
adenocarcinoma or other). The cervix tumor samples
were obtained during routine procedure for regular biopsy
or from paraffin embedded tissues. One hundred age-
matched women without history of cancer were enrolled
and served as normal controls. Upon signing an institu-
tionally approved informed consent, 5-ml blood samples
were withdrawn for the genetic study. The KFSHRC
Research Ethics Committee has approved the study (RAC #
2060 029).
DNA extraction, PCR amplification, DNA sequencing and
SNP genotyping
DNA was extracted using Puregene DNA Purification
Kit (Gentra System). The PCR primers used for amplifi-
cation were published previously [28]. Relevant segments
of DNA were amplified by thermal cycling (95°C for 15
min, 39 rounds of 95°C for 1 min, 56°C for 1 min and
72°C for 1 min and final extension at 72°C for 7 min)
using HotStarTaq DNA polymerase (Qiagen), and 50 ng
template DNA in 25 micro-litter volume with standard
reaction conditions. The amplified fragment was directly
sequenced using the DYEnamic ET Dye Terminator Cycle
Sequencing Kit (Amersham Biosciences) and were run on
the MegaBase 1000 sequencer (Applied Biosystems). Se-
quencing results were aligned to the corresponding refe-
rence sequence and the SNPs were genotyped using
SeqManII sequence analysis software (DNASTAR Inc.).
HPV detection and genotyping
We used the Linear Array HPV Genotyping Test (LA
HPV GT; Roche Diagnostics). The LA HPV GT is basedFigure 2 The distribution of squamous cell carcinoma and adenocarcon four major processes including DNA extraction, PCR
amplification of target DNA, hybridization of amplified
products to oligonucleotide probes and finally, the colori-
metric determination using the Linear Array Detection
Kit (LA DK). It enables the concurrent detection and
genotyping of 37 most common anogenital HPV DNA
genotypes [6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71,
72, 73 (MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8), 89
(CP6108) and IS39]. The test has the betaglobin gene as
an internal control to show adequacy of the sample. The
manufacturer states a sensitivity of 96% (95% CI: 92-98%)
and a specificity of 99% (95% CI: 98-100%) and has
included 3 controls, 2 negatives and 1 positive for HPV-16.
The kit also enables detection of multiple infections. The
primers and PCR reaction conditions were provided with
the test kit. The manufacturer’s recommended metho-
dology was strictly followed as also described previously
[17]. Positive reactions appear as blue bands on the test
strip. The strips were interpreted using the HPV reference
guide provided with the kit. Results were considered nega-
tive if no HPV band was detected after at least two repeated
testing.
Statistical analysis and ethical considerations
A total of 100 patients and 100 controls subjects were
included in the project following signing an informed
consent. Samples were coded with no identifiable per-
sonal data. HPV status was compared between the
patients in 5-year age groups. The association between
SNPs and cervical cancer was evaluated by the odd ratio
(OR) with its confidence interval. The degree of signifi-
cance was calculated using the Chi-Squares method. Ainoma by 5-year age group in 100 cervical cancer patients.
Table 1 Detection and Prevalence of different HPV
genotypes in 100 cervical cancer patients







HPV-16 HR 58 70.73
HPV-18 HR 3 3.66
HPV-31 HR 6 7.32
HPV-45 HR 3 3.66
HPV-56 HR 1 1.22
HPV-59 HR 1 1.22
HPV-73 HR 3 3.66
Co-infections:
HPV-16/18 HR/HR 3 3.66
HPV-16/39 HR/HR 1 1.22
HPV-16/70 HR/LR 1 1.22
HPV-35/52 HR/HR 1 1.22
HPV-45/59 HR/HR 1 1.22
LR: low risk; HR: high risk.
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ficant. Statistical analysis was carried out using the
SigmaPlot platform (Version 12.0, SPSS Science, IL, USA)
and the free online software: Case Control Studies, Tests
for Association, Institute of Human Genetics, Helmholtz
Center Munich, Germany (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl).Figure 3 The distribution of HPV detection and genotypes by 5-yearResults and discussion
Subjects and clinical data
Normal controls had similar socio-economic and demo-
graphic distribution and age range (30 to 73, median = 48)
as the patients. Age of patients at diagnosis of cervical
cancer ranged between 30 and 76 years, with a median of
46 years. The FIGO stage of the cancer ranged between
IA2 and IVA but most patients (n=76) had stage II/III
disease. By histology, 90 patients had squamous cell car-
cinoma while 10 had adenocarcinoma of the cervix. The
distribution of these two histopathological types by 5-year
age groups is given in Figure 2. Taking into consideration
two previously published data [17,18], adenocarcinoma
forms only 12% of cervical cancers compared to 88% of
squamous cell carcinoma.
HPV detection and genotyping
HPV detection and genotyping showed that 82 patients
(82%) were positive for HPV infection while 18 speci-
mens proved to be negative (18%) after at least two inde-
pendent testing. This prevalence of HPV infection in
Saudi cervical cancer patients is at the lower range of the
estimated 85% to 99% worldwide [5,7,30], and also
contrasting with the high burden estimated from previ-
ously published data from the extended Middle East and
North Africa that showed up to 98% positivity in women
with preinvasive and invasive lesions [31]. Khorasanizadeh
et al. has reported slightly lower prevalence (76%) in a
nearby country [19].
By histology, 60% of adenocarcinomas and 84% of
squamous cell carcinomas were HPV-positive. Linear
Array HPV genotyping test had detected seven different
single HPV genotypes and five double infections in thisage group in 100 cervical cancer patients.
Table 2 Genotypes’ and alleles’ frequencies of 7 assessed
polymorphisms in 100 cervix carcinoma patients in











Odds ratio P- Value
(95% CI)
(%, n = 100) (%, n = 100)
CDKN1A (p21) codon 31 C>A Ser/Arg rs1801270
C/C 64 (64) 62 (62)
C/A 32 (32) 35 (35) 0.89 (0.49-1.60) 0.69
A/A 4 (4) 3 (3) 1.29 (0.28-6.01) 0.74
C 160 (80) 159 (79)
A 40 (20) 41 (21) 0.97 (0.59-1.58) 0.90
TP53 (p53) codon 72 G>C Arg/Pro rs1042522
G/G 20 (20) 22 (22)
G/C 58 (58) 52 (52) 1.23 (0.60-2.50) 0.57
C/C 22 (22) 26 (26) 0.93 (0.41-2.14) 0.87
G 98 (49) 96 (48)
C 102 (51) 104 (52) 0.96 (0.65-1.42) 0.84
ATM codon 1853 G>A Asp/Asn rs1801516
G/G 90 (90) 88 (88)
G/A 8 (8) 12 (12) 0.65 (0.25-1.67) 0.37
A/A 2 (2) 0 (0) 4.89 (0.23-103.2) 0.16
G 188 (94) 188 (94)
A 12 (6) 12 (6) 1.00 (0.44-2.28) 1
HDM2 promoter 309 T>C rs2279744
T/T 30 (30) 27 (27)
T/C 46 (46) 44 (44) 0.94 (0.48-1.83) 0.86
C/C 24 (24) 29 (29) 0.75 (0.35-1.58) 0.44
T 106 (53) 98 (49)
C 94 (47) 102 (51) 0.85 (0.58-126) 0.42
TGFβ1 codon 10 T>C Leu/Pro rs1982073
T/T 48 (48) 39 (39)
T/C 31 (31) 38 (38) 0.89 (0.42-1.91) 0.77
C/C 21 (21) 23 (23) 1.35 (0.65-2.79) 0.42
T 127 (64) 116 (58)
C 73 (37) 84 (42) 1.26 (0.84-1.88) 0.26
XRCC1 codon 399 G>A Arg/Gln rs25487
G/G 52 (52) 59 (59)
G/A 34 (34) 40 (40) 0.96 (0.54-1.74) 0.90
A/A 14 (14) 1 (1) 15.88 (2.0-124.9)) 0.0007
G 138 (69) 158 (79)
A 62 (31) 42 (21) 1.69 (1.07-2.66) 0.02
XRCC3 codon 241 C>T Thr/Met rs861539
C/C 45 (45) 41 (41)
C/T 44 (44) 37 (37) 1.08 (0.59-1.99) 0.79
Table 2 Genotypes’ and alleles’ frequencies of 7 assessed
polymorphisms in 100 cervix carcinoma patients in
addition to 100 age-and-gender matched control
volunteers without cancers (Continued)
T/T 11 (11) 22 (22) 0.46 (0.20-1.05) 0.06
C 134 (67) 119 (60)
T 66 (33) 81 (41) 0.72 (0.48-1.09) 0.12
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distribution of HPV detection and genotypes is shown in
Figure 3. Furthermore, age-specific HPV distribution in
the Saudi cervical cancer patients showed a bimodal
curve with a first peak at younger ages (41–50 years)
and a relative rebound at older ages (56–60 years) as it
has been described in other population [32].
The most common HPV genotypes were HPV-16 (71%),
followed by HPV-31 (7%), HPV-18, 45, 73 (4% each).
Seven patients had double infections involving HPV-16/18
(4%), HPV-16/39, 16/70, 35/52, and 45/59 (1% each). In
agreement with other studies, the most common HPV
genotype was HPV-16 [33] with an overall prevalence,
including co-infections, of 77% compared to 54% in the
world [30]. In addition, HPV-16 and/or HPV-18 were
present in 66% (66/100) of all patients and formed
together 80% (66/82) of all HPV positive patients. This is
slightly higher than the prevalence observed in Europe
(74.5%), North America (76.5%) and in the whole world
(70.9%). These results are close to those reported in
another neighboring country where HPV-16 (54%), HPV-
18 (14%), and HPV-31 (6%) were the most commonly
detected in cervical cancer patients [19]. However, our
results seem to be different from those obtained in other
Middle Eastern country where the most common HPV
genotype was HPV-33, which was not detected in our
patients, followed by HPV-16 and HPV-18 [34].
Genetic polymorphic variations
Genetic polymorphic variation in candidate SNPs were
determined for all 100 cervical cancer patients in
addition to the 100 age-matched female volunteers with-
out cancer (controls). The two SNPs, LIG4 rs2232641
and HDM2 rs11177386 were all majority alleles, and
therefore, were omitted from the analysis. Cancer predis-
position study showed significant association between
XRCC1 rs25487 and having cervical cancer (Table 2).
Patients harboring the variant allele (A, Gln) have about
2-fold increased risk to develop cervical cancer (P = 0.02).
These results suggest that the variant (or minority) allele
could confer higher susceptibility to cervical cancer and
probably the HPV-related transformation.
Indeed, the analysis of this nested case–control study
shows that 93% (13/14) of patients with homozygous
variant alleles (A/A) are HPV-positive compared to 82%
Alsbeih et al. Infectious Agents and Cancer 2013, 8:15 Page 6 of 8
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allele (G/G), suggesting a trend toward an association
between the HPV-positivity and XRCC1 G399A geno-
type; however, it did not reach statistical significance
(P = 0.28; Table 3). To check for skewness in the distri-
bution of XRCC1 G399A genotypes, we tested for devi-
ation from Hardy-Weinberg equilibrium (HWE), by
comparing observed-to-expected distributions in HPV-
positive (cases) and HPV-negative (controls) patients
(Table 3). Results showed statistically significant devi-
ation from HWE for cases (P = 0.03) but not for the
controls. Therefore, in HPV+ cervical cancer patients,
the null hypothesis that the population is in Hardy–
Weinberg frequencies is rejected, which put forward the
hypothesis of probable selection. This suggests that the
co-occurrence of XRCC1 G399A genotypes and HPV-
positive cancer is not random, thus, implicating this
SNP as a susceptibility locus to develop cervical cancer.
At the molecular level, XRCC1 protein is required for
efficient DNA single-strand breaks repair to maintain





(HPV+) (n = 82) (HPV-) (n = 18)
XRCC1 codon 399 G>A
Genotype
G/G 42 (51) 11 (61)
G/A 27 (33) 6 (33)
A/A 13 (16) 1 (6)
G/A+A/A 40 (49) 7 (39)
Allele
G 111 (68) 28 (78)
A 53 (32) 8 (22)
Armitages’ trend test
Significance level (P-value) for deviation from HWE
TP53 (p53) codon 72 G>C
Genotype
G/G 18 (22) 2 (11)
G/C 49 (60) 9 (50)
C/C 15 (18) 7 (39)
G/C+C/C 64 (78) 9 (89)
Allele
G 85 (52) 13 (36)
C 79 (48) 23 (64)
Armitages’ trend test:
Significance level (P-value) for deviation from HWE
HWE: Hardy-Weinberg Equilibrium. OR: Odds Ratio.
Computed online at: http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.reduction leads to increased sensitivity to cell killing by
ionizing radiation [35]. The codon 399 is situated in the
BRCT I active domain of the protein and could possibly
affect its function [36]. In addition, this SNP was asso-
ciated with cellular and clinical sensitivity to cancer
treatment [37] and has recently been implicated in suscep-
tibility to cervical cancer among Asian women [38].
In contrast, no association was found for TP53 G72C
where cancer patients and controls without cancer have
showed similar frequencies (Table 3). Nonetheless, nested
analysis showed that 90% of patients with majority (G/G)
allele were HPV-positive compared to 74% of heterozy-
gous (G/C), and 68% of homozygous (C/C) variant allele,
revealing a preponderance of HPV-positivity in patients
harboring the majority (G) allele. In fact, this allele has
been suggested to be more susceptible to high-risk HPV
E6 degradation [24]. In addition, statistical analysis
showed a trend towards an association between TP53
G72C SNP genotype and HPV infection (P = 0.06;
Table 3). Furthermore, testing for deviation from HWE
also showed a borderline significant deviation (P = 0.07)eviation from Hardy-Weinberg Equilibrium





1.18 (0.39-3.56) 0.77 35.87 6.22
3.41 (0.40-28.93) 0.24 8.56 0.89
1.49 (0.53-4.24) 0.45
1.67 (0.71-3.91) 0.23




0.61 (0.12-3.07) 0.54 40.95 8.31
0.24 (0.04-1.32) 0.08 19.03 7.35
0.44 (0.09-2.12) 0.29
0.53 (0.25-1.11) 0.09
Common OR= 0.48 0.06
0.07 0.72
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ation was observed for HPV-negative controls. Again,
these results suggest that cervical cancer occurrence is not
random in the population and that certain factors such as
genetic SNPs, for instance having the XRCC1 A-allele or
the TP53 G-allele in connection with HPV infection,
favors its development. To answer the question whether
these 2 SNPs exhibit cumulative effect towards HPV
mediated cervical cancer, , we have computed the number
of risk alleles for XRCC1 and TP53 in patients and
controls. Although the patients had higher median num-
ber of risk alleles (2 compared to 1), the difference was
not statistically significant (Mann–Whitney rank sum test,
P = 0.12) suggesting independent effects.
Since the first identification of the potential role of Arg/
Arg genotype as a risk marker for uterine cervix neoplasia
[24], there have been many studies that investigated the
association between the TP53 codon 72 polymorphism
and cervical cancer in various populations; however,
results were inconsistent [29]. Although several factors
were proposed as contributing factors to the discrepan-
cies, the deviation from the Hardy-Weinberg equilibrium
was identified as a principal source of divergent results
[39]. Nonetheless, there is sufficient evidence to support a
positive association particularly when HPV status and/or
histopathology is known. Thus, while Sousa et al. failed to
confirm the association in most European countries,
except Italy and United Kingdom [40], two other meta-
analyses confirmed the association of homozygous Arg
with invasive cervical cancer [39,41], In line with our
results, a recent family-based association study where
HPVs status was also determined, Hu et al. confirmed that
the TP53 codon 72 G (arginine) is significantly overtran-
smitted in Caucasian cervical cancer subjects, especially in
cases infected with HPV16- and/or HPV-18 [29].
Conclusions
The prevalence of HPV infection in invasive cervical
cancer in Saudi Arabia (82%) is at the lower range of
that observed in the world (85%-99%), the most com-
mon HPV genotype was by far HPV-16 (71%), followed
by HPV-31 (7%), HPV-18, 45, and 73 (4% each) with
double infections were present in 8.5% of HPV-positive
patients. Genetic predisposition showed that among the
nine SNPs studied, only XRCC1 G399A was significantly
(P = 0.02) associated with cervical cancer, while TP53
G72C showed borderline association (P = 0.06) only in
HPV-positive patients. In addition, both SNPs showed
degrees of deviation from Hardy-Weinberg equilibrium
only in HPV-infected tumors, indicative of non-random
distribution, hence implicating the combination of HPV
and SNPs in cancer predisposition. Thus, SNPs could be
more relevant biomarkers of susceptibility to cervical
cancer when associated with HPV infection. Furtherstudies with larger cohort are needed to confirm these
results and better postulate the use of SNPs as bio-
markers of susceptibility to cervical cancer.
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